A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-1287 administered daily to patients with advanced solid tumors.

被引：0

作者：

Ben George

Richards, Donald A.

Edenfield, William Jeffory

Warner, Steven L.

Mouritsen, Lars

Bishop, Reyna

Anthony, Stephen Patrick

Bearss, David

Vogelzang, Nicholas J.

Whatcott, Clifford

机构：

[1] Froedtert, Milwaukee, WI USA

[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[3] US Oncol Res, Tyler, TX USA

[4] Prisma Hlth Upstate Canc Inst, Inst Translat Oncol Res, Greenville, SC USA

[5] Tolero Pharmaceut Inc, Lehi, UT USA

[6] Comprehens Canc Ctr Nevada, Las Vegas, NV USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3611

引用

页数：1